- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Kura Oncology Inc (KURA)
Kura Oncology Inc stock price live, this page displays NASDAQ KURA stock exchange data. View the KURA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Kura Oncology Inc real time stock price chart below.
What Is the Kura Oncology Inc Stock Price Today?
The Kura Oncology Inc stock price today is 6.62.
What Is the Stock Symbol for Kura Oncology Inc?
The stock symbol for Kura Oncology Inc is ""KURA.""
What Stock Exchange Does Kura Oncology Inc Trade On?
Kura Oncology Inc is listed and trades on the NASDAQ stock exchange.
Is Kura Oncology Inc a Good Stock to Buy?
Determining whether Kura Oncology Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the KURA quote. (ISIN: US50127T1097)
What Is the Kura Oncology Inc Stock Price Today?
The Kura Oncology Inc stock price today is 6.62.
What Is the Stock Symbol for Kura Oncology Inc?
The stock symbol for Kura Oncology Inc is ""KURA.""
What Stock Exchange Does Kura Oncology Inc Trade On?
Kura Oncology Inc is listed and trades on the NASDAQ stock exchange.
Is Kura Oncology Inc a Good Stock to Buy?
Determining whether Kura Oncology Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the KURA quote. (ISIN: US50127T1097)
6.62
-0.06(-0.82%)
Real-time Data·
Fair Value
An estimate of a Kura Oncology Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.48
6.74
52 wk Range
5.41
21.60
KURA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 8 days
More Info
Fair Value
An estimate of a Kura Oncology Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.486.74
52 wk Range
5.4121.60
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
KURA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Kura Oncology Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
25.92
Upside
+291.49%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
- Form 8K Kura Oncology Inc For: 1 July
- Investing.com
- Form 8K Kura Oncology Inc For: 1 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Kura Oncology Inc Company Profile
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.
Kura Oncology Inc SWOT Analysis
Ziftomenib's Promise | Explore Kura Oncology's lead candidate ziftomenib, showing potential in AML treatment with promising clinical trial results and a differentiated safety profile |
Financial Fortitude | Kura's robust cash position of over $700 million, bolstered by strategic partnerships, provides ample runway for clinical development and potential commercialization |
Market Opportunity | Delve into the estimated $1 billion addressable market for AML treatment and Kura's potential to capture significant share with ziftomenib's unique positioning |
Analyst Optimism | Analysts maintain a strong buy consensus with price targets ranging from $11 to $40, reflecting confidence in Kura's pipeline and market potential |
Kura Oncology Inc Earnings Call Summary for Q1/2025
- Q1 2025 revenue reached $14.1M, up from $0 in Q1 2024; EPS at -$0.66, slightly below -$0.62 forecast
- Stock rose 1.69% after-hours despite EPS miss; cash position strong at $703.2M, funding operations into 2027
- R&D expenses increased to $56M from $36.3M in Q1 2024; net loss widened to $57.4M from $49.5M
- Company advancing pipeline with new trials; potential Ziftomenib launch for AML and FTI program progress
- Management confident in product pipeline; exploring combination strategies in various cancer indications
Last Updated: 01/05/2025, 22:36
Read Full TranscriptCompare KURA to Peers and Sector
Metrics to compare | KURA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKURAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.2x | −2.0x | −0.5x | |
PEG Ratio | −0.77 | −0.02 | 0.00 | |
Price/Book | 1.6x | 3.5x | 2.6x | |
Price / LTM Sales | 8.4x | 82.8x | 3.2x | |
Upside (Analyst Target) | 319.8% | 179.6% | 42.7% | |
Fair Value Upside | Unlock | 4.4% | 5.8% | Unlock |
Analyst Ratings
13 Buy
2 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 25.92
(+291.49% Upside)
Earnings
Latest Release
May 01, 2025
EPS / Forecast
-0.66 / -0.62
Revenue / Forecast
14.11M / 13.37M
People Also Watch
FAQ
What Stock Exchange Does Kura Oncology Inc Trade On?
Kura Oncology Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Kura Oncology Inc?
The stock symbol for Kura Oncology Inc is "KURA."
What Is the Kura Oncology Inc Market Cap?
As of today, Kura Oncology Inc market cap is 570.53M.
What Is Kura Oncology Inc's Earnings Per Share (TTM)?
The Kura Oncology Inc EPS (TTM) is -2.09.
When Is the Next Kura Oncology Inc Earnings Date?
Kura Oncology Inc will release its next earnings report on 30 Jul 2025.
From a Technical Analysis Perspective, Is KURA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Kura Oncology Inc Stock Split?
Kura Oncology Inc has split 0 times.
How Many Employees Does Kura Oncology Inc Have?
Kura Oncology Inc has 192 employees.
What is the current trading status of Kura Oncology Inc (KURA)?
As of 23 Jul 2025, Kura Oncology Inc (KURA) is trading at a price of 6.62, with a previous close of 6.67. The stock has fluctuated within a day range of 6.48 to 6.74, while its 52-week range spans from 5.41 to 21.60.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.